Background: Since antigen-specific IgE and eosinophils are major inducing factors of allergic inflammation of the airways, both factors are therapeutic targets of asthma. We investigated the effects of ONO-4007, a nontoxic lipid A analogue, on antigen-specific antibody response and the recruitment of eosinophils into airways in murine systems. Methods: BALB/c mice were injected ONO-4007 intraperitoneally during sensitization with ovalbumin (OVA) and aluminium hydroxide to determine its effects on the antigen-specific antibody response. ONO-4007 was also injected intravenously during either systemic sensitization and inhalation with OVA, or sensitization or inhalation alone to determine its effects on antigen-induced airway inflammation. In vitro effects of ONO-4007 on the functional differentiation of naive CD4+ T cells were investigated by culturing naive CD4+ T cells derived from DO11.10 mice and OVA-pulsed dendritic cells (CDCs) with ONO-4007. Results: ONO-4007 inhibited antigen-specific IgE and IgG1, but not IgG2a responses. ONO-4007 decreased the recruitment of eosinophils and the levels of IL-5 in bronchoalveolar lavage fluid, not only when it was injected during systemic sensitization and inhalation with OVA, but also during inhalation alone. ONO-4007 inhibited the differentiation of IL-4- and IL-13-producing CD4+ T cells in vitro, which was partly mediated by DCs. Conclusions: ONO-4007 inhibited antigen-specific IgE and IgG1 responses and antigen-induced eosinophil recruitment into the airways in BALB/c mice. These effects were mediated, at least partly, by the modulation of DCs, although there may also be other mechanisms.

Keywords:
ONO-4007, Lipid A analogue, IgE, IL-4, IL-5, Eosinophil, Th2, Dendritic cell
1.
Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1986;12:227–257.
2.
Umetsu DT, DeKruyff RH: Th1 and Th2 CD4+ T cells in human allergic diseases. J Allergy Clin Immunol 1997;100:1–6.
3.
Jabara HH, Fu SM, Geha RS, Vercelli D: CD40 and IgE: Synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990;172:1861–1864.
4.
Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE: Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90:3730–3734.
5.
Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harada N, Tominaga A, Takaku K: Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988;167:43–56.
6.
Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA: Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141–5145.
7.
Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, Hsieh KH: Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996;2:540–544.
8.
Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT: An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997;158:4137–4144.
9.
Hansen G, McIntire JJ, Yeung P, Berry G, Thorbecke GJ, Chen L, Dekruyff RH, Umetsu DT: CD4+ T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest 2000;105:61–70.
10.
Yang R-B, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL, Godowski PJ: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998;395:284–288.
11.
Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M: Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998;188:2091–2097.
12.
Galanos C, Luderitz O, Rietschel ET, Westphal O, Brade H, Brade L, Freudenberg M, Schade U, Imoto M, Yoshimura H, Kusumoto S, Shima T: Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985;148:1–5.
13.
Westphal O, Luderitz O, Galanos C, Mayer H, Rietschel ET: The story of bacterial endotoxin. Adv Immunopharmacol 1986;3:13–34.
14.
Yang D, Satoh M, Ueda H, Tsukagoshi S, Yamazaki M: Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 1994;38:287–293.
15.
Hattori Y, Szabo C, Gross S, Thiemermann C, Vane JR: Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. Eur J Pharmacol 1995;291:83–90.
16.
Murphy KM, Heimberger AB, Loh DY: Induction by antigen of intrathymic apoptosis of CD4+CD8+ TCRlow thymocytes in vivo. Science 1990;250:1720–1723.
17.
Nagai H, Takeda H, Yamaguchi S, Tanaka H, Matsuo A, Inagaki N: The effect of a thromboxane A2 receptor antagonist BAY-u-3405 on experimental allergic reactions. Prostaglandins 1995;50:75–87.
18.
Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M, Koyasu S: Interleukin 12-dependent interferon γ production by CD8α+ lymphoid dendritic cells. J Exp Med 1999;189:1981–1986.
19.
Snapper CM, Paul W: Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987;236:944–947.
20.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y-J, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767–811.
21.
Rescigno M, Granucci F, Citterio S, Foti M, Ricciardi-Castagnoli P: Coordinated events during bacteria-induced DC maturation. Immunol Today 1999;20:200–203.
22.
de Bono JS, Dalgleish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D, Ellard S, Gordon RJ, Brindley CJ, Evans TR: Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000;6:397–405.
23.
Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311–316.
24.
Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K, Akira S: Cutting edge: Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J Immunol 2000;164:3476–3479.
25.
Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel F-B: Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033–1039.
26.
Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR: Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993;8:35–42.
27.
Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR: Activation of CD4+ T cell, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993;92:313–324.
28.
Poltorak A, He X, Smirnova I, Liu M-Y, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998;282:2085–2088.
29.
Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the lps gene product. J Immunol 1999;162:3749–3752.
30.
Seder RA, Paul WE: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635–673.
31.
Constant SL, Bottomly K: Induction of TH1 and TH2 CD4+ T cell responses: The alternative approaches. Annu Rev Immunol 1997;15:297–322.
32.
Dong C, Juedes AE, Temann U-A, Shresta S, Allison JP, Ruddle NH, Flavell RA: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97–101.
33.
Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, Nguyen T, Burwell T, Schneider H, Gonzalo JA, Gosselin M, Owen LR, Rudd CE, Gutierrez-Ramos JC: The CD28-related molecules ICOS is required for effective T cell-dependent immune responses. Immunity 2000;13:95–105.
34.
Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Moser M: CD8α+ and CD8α– subclasses of dendritic cell direct the development of distinct T helper cell in vivo. J Exp Med 1999;189:587–592.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.